How Employers Can Build a Smarter GLP-1 Benefit

GLP-1 medications have changed the conversation around obesity, diabetes, cardiometabolic risk, and employer-sponsored health plans.

And frankly, employers cannot afford to ignore them.

But they also cannot afford to cover them blindly.

That is the tension.

On one hand, obesity and metabolic disease are not “lifestyle problems” in the simplistic way our healthcare system has too often framed them. They are complex, chronic, progressive conditions tied to heart disease, diabetes, kidney disease, sleep apnea, joint deterioration, cancer risk, disability, absenteeism, and overall quality of life.

On the other hand, GLP-1 medications are expensive. If a self-funded employer opens the door without a thoughtful strategy, the plan can experience rapid cost escalation without necessarily improving long-term outcomes.

So the real question is not, “Should employers cover GLP-1s?”

The better question is:

How do employers build a smarter GLP-1 benefit that improves health, protects the plan, and supports the member for the long game?

Obesity Is a Serious Health Risk — Not a Character Flaw

We need to start with the truth.

Obesity is one of the most significant drivers of chronic disease in this country. CDC data shows that adult obesity prevalence was 40.3% during August 2021 through August 2023. Severe obesity was 9.4% during that same period. Source: CDC

That matters because obesity does not live in isolation.

It often travels with hypertension, insulin resistance, type 2 diabetes, fatty liver disease, obstructive sleep apnea, orthopedic issues, cardiovascular disease, depression, infertility concerns, and chronic inflammation.

For employer-sponsored plans, that means obesity is not only a pharmacy issue. It is a medical-cost issue, a productivity issue, a disability issue, and a long-term risk issue.

The GLP-1 conversation must move beyond vanity weight loss.

This is about cardiometabolic risk management.

GLP-1s Are Not Magic — But They Are Clinically Meaningful

GLP-1s and related incretin medications have created real clinical momentum because they address biology in a way that traditional “eat less and move more” advice never fully did.

The FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, making it the first weight-loss medication approved for that cardiovascular risk-reduction indication. Source: FDA

The FDA also approved Zepbound as the first medication for moderate to severe obstructive sleep apnea in adults with obesity, reflecting the growing understanding that weight reduction can meaningfully improve obesity-related comorbid conditions. Source: FDA

That is important.

These medications are no longer just part of a weight-loss conversation. They are part of a broader chronic disease, cardiometabolic, and risk-reduction conversation.

But let’s be clear: a medication-only strategy is not a health strategy.

The Mistake Employers Make: Covering the Drug Without Building the Program

The biggest mistake employers can make is treating GLP-1 coverage like a simple pharmacy toggle.

Turn it on. Turn it off. Cover it. Exclude it. Prior authorize it. Deny it.

That approach misses the bigger picture.

If an employer covers GLP-1s without clinical structure, they may pay a premium price without ensuring the right members are receiving the medication, the right comorbidities are being addressed, the member is receiving nutrition and lifestyle support, side effects are being managed, adherence is being monitored, and outcomes are being measured.

That is not strategy.

That is spend.

A smarter GLP-1 benefit should answer these questions:

• Who qualifies?
• What clinical criteria must be met?
• What lifestyle support is required?
• How will continuation of therapy be measured?
• How will we prevent inappropriate use?
• How will we support members who stop therapy?
• How will we track outcomes beyond pounds lost?
• How will this benefit integrate with diabetes, hypertension, CKD, cardiac, oncology, maternity, and behavioral health risk?

That is where employers need to be much more disciplined.

A Smarter GLP-1 Benefit Has Guardrails — Not Barriers

There is a difference between a barrier and a guardrail.

A barrier blocks access without regard for clinical need.

A guardrail protects the member and the plan by making sure the right care is delivered to the right person, at the right time, for the right reason, with the right support.

A responsible GLP-1 benefit may include:

Clinical eligibility criteria. This may include BMI thresholds, obesity-related comorbidities, type 2 diabetes, cardiovascular risk, sleep apnea, hypertension, or other high-risk indicators.

Prior authorization. Not as a blunt-force denial tool, but as a way to validate medical necessity and align use with evidence-based criteria.

Step therapy where appropriate. For some members, lower-cost interventions or alternative therapies may be clinically appropriate before moving to higher-cost medications.

Lifestyle and nutrition support. Medication without behavior change is incomplete care. Members need support around protein intake, hydration, resistance training, sleep, stress, and long-term habit formation.

Care navigation. Members need help understanding where to receive care, how to access medications safely, how to avoid scams or unsafe compounded products, and how to coordinate with their provider.

Ongoing monitoring. Weight is not the only metric. Employers should also be looking at A1C, blood pressure, lipids, sleep apnea improvement, medication adherence, adverse effects, ER visits, disability risk, and avoidable progression of disease.

Continuation criteria. If the medication is not working, is not being taken, or is not clinically appropriate, the plan should not continue paying indefinitely without review.

That is not rationing care.

That is responsible stewardship.

Employers Should Think in Risk Tiers

Not every member needs the same level of support.

A smart benefit design should stratify members based on risk.

Tier 1: Early Risk and Prevention

These are members with obesity or early metabolic risk who may benefit from digital tools, coaching, nutrition education, movement support, and behavior-change programs.

The goal is to prevent progression.

Tier 2: Moderate Risk

These members may have dual conditions such as obesity plus hypertension, prediabetes, hyperlipidemia, sleep apnea, or early kidney-risk indicators.

They may need more personalized coaching, care coordination, and physician engagement.

The goal is to reverse risk where possible and stabilize disease progression.

Tier 3: High Risk and Polymorbid

These are members with obesity plus multiple advancing conditions — diabetes, CKD, cardiac disease, sleep apnea, orthopedic deterioration, high pharmacy spend, recurrent admissions, or rising total cost of care.

This group needs high-touch clinical management.

The goal is to reduce severity, prevent catastrophic claims, improve quality of life, and protect the plan from avoidable high-cost events.

This is where GLP-1 strategy becomes more than a pharmacy benefit.

It becomes a medical management strategy.

The ROI Conversation Needs to Mature

Employers want to know: “Will GLP-1 coverage save money?”

That is a fair question.

But the answer is not always clean in a 12-month spreadsheet.

Some benefits may take time to show up. Improved A1C, lower blood pressure, fewer joint replacements, fewer cardiac events, fewer diabetes complications, better sleep, improved productivity, and reduced disability risk may not fully materialize in one plan year.

At the same time, employers cannot write a blank check and hope savings arrive someday.

That is why outcomes tracking matters.

A mature ROI model should include:

• Medical spend trend
• Pharmacy spend trend
• Total cost of care
• Weight-loss response
• A1C improvement
• Blood pressure improvement
• Reduction in diabetes medication burden where appropriate
• Sleep apnea improvement
• Avoided procedures or delayed orthopedic deterioration
• Reduced ER and inpatient utilization
• Employee retention and productivity
• Member satisfaction
• Engagement with coaching and care management

The employer should not simply ask, “How much did the drug cost?”

They should ask, “What value did we receive for the investment?”

Those are very different questions.

The Stop-Loss and High-Cost Claim Angle

For self-funded employers, GLP-1 strategy should also be viewed through a stop-loss lens.

Poorly controlled obesity-related disease can contribute to catastrophic claims over time: myocardial infarction, stroke, dialysis, advanced diabetes complications, complex orthopedic surgery, high-risk pregnancy complications, wound care, sleep-apnea-related cardiovascular events, and more.

A GLP-1 benefit will not eliminate those risks.

But when targeted correctly, it may become part of a broader strategy to reduce the incidence and severity of high-cost claims.

That is the key.

GLP-1s should not sit off to the side as a pharmacy trend problem.

They should be integrated into the employer’s larger risk-management strategy.

What Employers Should Avoid

Employers should be very cautious about:

• Covering GLP-1s with no clinical criteria
• Allowing indefinite continuation without outcome review
• Failing to integrate lifestyle support
• Ignoring members who discontinue therapy
• Relying only on pharmacy benefit manager reporting
• Failing to coordinate with disease management and case management
• Treating obesity as separate from diabetes, kidney disease, cardiac disease, maternity risk, and cancer risk
• Making decisions based only on short-term cost panic

The worst strategy is reactive benefit design.

Employers should not wait until GLP-1 spend explodes and then abruptly cut off access. That creates member disruption, provider abrasion, HR frustration, and reputational risk.

Plan ahead.

Build the structure before the spend becomes unmanageable.

What a Better Employer Strategy Looks Like

A smarter GLP-1 benefit should be clinically sound, financially disciplined, and human.

That means:

• Recognizing obesity as a chronic condition
• Prioritizing members with the highest clinical need
• Requiring meaningful lifestyle and care-management support
• Measuring outcomes over time
• Coordinating pharmacy and medical data
• Supporting members with compassion, not shame
• Protecting the plan from inappropriate or low-value utilization
• Using the benefit as part of a broader chronic disease strategy

This is how employers move from “Are we covering weight-loss drugs?” to “Are we improving the health trajectory of our people?”

That is the conversation we should be having.

Final Thought

GLP-1s are not the enemy.

Unmanaged spend is the enemy.

Poor benefit design is the enemy.

Fragmented care is the enemy.

Ignoring obesity until it becomes diabetes, kidney disease, heart disease, disability, or a catastrophic claim is the enemy.

Employers have an opportunity right now to build something better — a benefit that is thoughtful, clinically appropriate, financially sustainable, and deeply human.

Because at the end of the day, the goal is not just weight loss.

The goal is healthier people, stronger families, better workplaces, and health plans that actually work.

That is what a smarter GLP-1 benefit should do.